Published in J Urol on July 01, 1993
An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int (2012) 2.77
Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen. Urology (2010) 2.27
Multiparametric magnetic resonance imaging in prostate cancer: present and future. Curr Opin Urol (2008) 2.23
Critical review of prostate cancer predictive tools. Future Oncol (2009) 1.57
Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PLoS One (2011) 1.55
Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. Neoplasia (2001) 1.52
HDR Brachytherapy in the Management of High-Risk Prostate Cancer. Adv Urol (2012) 1.45
Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol (1993) 1.43
Novel diagnostic biomarkers for prostate cancer. J Cancer (2010) 1.36
Advances in MR spectroscopy of the prostate. Magn Reson Imaging Clin N Am (2008) 1.24
Predictive models in external beam radiotherapy for clinically localized prostate cancer. Cancer (2009) 1.23
Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique. Am J Pathol (1997) 1.23
The changing pattern of prostate cancer in Nigerians: current status in the southeastern states. J Natl Med Assoc (2002) 1.21
Determinants of mortality following a diagnosis of prostate cancer in Veterans Affairs and private sector health care systems. Am J Public Health (2003) 1.19
Prognostic factors for failure after prostatectomy. J Cancer (2010) 1.08
Carboxypeptidase 4 gene variants and early-onset intermediate-to-high risk prostate cancer. BMC Cancer (2009) 1.07
Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer. Am J Pathol (1997) 1.06
Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy. BJU Int (2012) 1.03
Positive surgical margins during robotic radical prostatectomy: a contemporary analysis of risk factors. BJU Int (2008) 1.03
Prognostic factors in prostate cancer. Diagn Pathol (2006) 0.99
Enzymatically active prostate-specific antigen promotes growth of human prostate cancers. Prostate (2011) 0.97
Radiation therapy failure in prostate cancer patients: risk factors and methods of detection. Rev Urol (2002) 0.96
Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer. J Urol (2008) 0.96
Matrix metalloproteinases and angiogenic factors: predictors of survival after radical prostatectomy for clinically organ-confined prostate cancer? Am J Pathol (2010) 0.95
External validation of the cancer of the prostate risk assessment (CAPRA) score in a single-surgeon radical prostatectomy series. Urol Oncol (2010) 0.94
Molecular staging by RT-pCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer. Clin Exp Metastasis (2004) 0.92
Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406. Int J Radiat Oncol Biol Phys (2012) 0.91
Selecting candidates for radical prostatectomy. Rev Urol (2000) 0.89
Molecular and genetic prognostic factors of prostate cancer. World J Urol (2003) 0.89
Prostate-specific antigen screening can be beneficial to younger and at-risk men. CMAJ (2012) 0.88
Prostate-specific antigen screening: pro. Curr Opin Urol (2010) 0.88
Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer. Mol Cancer Res (2011) 0.88
Can we predict real T3 stage prostate cancer in patients with clinical T3 (cT3) disease before radical prostatectomy? Yonsei Med J (2010) 0.88
Nuclear morphometry, nucleomics and prostate cancer progression. Asian J Androl (2012) 0.86
Genetic background influences murine prostate gene expression: implications for cancer phenotypes. Genome Biol (2007) 0.86
Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer. World J Urol (2004) 0.85
Nomograms for the prediction of pathologic stage of clinically localized prostate cancer in Korean men. J Korean Med Sci (2005) 0.85
Lymphotropic nanoparticle enhanced MRI for the staging of genitourinary tumors. Nat Rev Urol (2010) 0.85
Advances in brachytherapy. Rev Urol (2004) 0.85
Phase II trial of GM-CSF in advanced prostate cancer. Invest New Drugs (2001) 0.85
Neoadjuvant Therapy for Prostate Cancer: An Oncologist's Perspective. Rev Urol (2003) 0.84
Recent advances: urology. BMJ (2000) 0.84
Robotic-assisted laparoscopic prostatectomy. Br J Cancer (2009) 0.83
Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm. Cancer Treat Rev (2012) 0.83
Improving prediction of prostate cancer recurrence using chemical imaging. Sci Rep (2015) 0.82
Evaluation of prediction models for the staging of prostate cancer. BMC Med Inform Decis Mak (2013) 0.81
Prostate cancer: epidemiology and screening. Rev Urol (2000) 0.81
Development of a real-time clinical decision support system upon the Web MVC-based architecture for prostate cancer treatment. BMC Med Inform Decis Mak (2011) 0.80
Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol (1994) 0.79
Cancer imaging: is it cost-effective? Cancer Imaging (2004) 0.79
Genomic Copy Number Variations in the Genomes of Leukocytes Predict Prostate Cancer Clinical Outcomes. PLoS One (2015) 0.78
Intranodal signal suppression in pelvic MR lymphography of prostate cancer patients: a quantitative comparison of ferumoxtran-10 and ferumoxytol. PeerJ (2016) 0.78
Multiparametric MRI guidance in first-time prostate biopsies: what is the real benefit? Diagn Interv Radiol (2015) 0.78
The importance of pelvic lymph node dissection in men with clinically localized prostate cancer. Rev Urol (2006) 0.78
Correlation of endorectal coil magnetic resonance imaging of the prostate with pathologic stage. World J Urol (2004) 0.78
Phase II trial of neoadjuvant docetaxel and CG1940/CG8711 followed by radical prostatectomy in patients with high-risk clinically localized prostate cancer. Oncologist (2013) 0.78
Risk stratification of prostate cancer: integrating multiparametric MRI, nomograms and biomarkers. Future Oncol (2016) 0.78
A prospective study of nomogram-based adaptation of prostate radiotherapy target volumes. Radiat Oncol (2015) 0.77
Diagnosis of prostate cancer via nanotechnological approach. Int J Nanomedicine (2015) 0.77
Re: High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized cancer. J Urol (2001) 0.77
Prostate Cancer - Old Problems and New Approaches. (Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects). Pathol Oncol Res (1996) 0.76
Multiple comparisons permutation test for image based data mining in radiotherapy. Radiat Oncol (2013) 0.75
The use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective randomised trials. Br J Cancer (2004) 0.75
Current technique and results for extended pelvic lymph node dissection during robot-assisted radical prostatectomy. Investig Clin Urol (2016) 0.75
Usefulness of Total PSA Value in Prostate Diseases Diagnosis. Acta Inform Med (2016) 0.75
Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2010) 0.75
Evaluation of eight plasma proteins as candidate blood-based biomarkers for malignant gliomas. Cancer Invest (2014) 0.75
The long-term outcomes after radical prostatectomy of patients with pathologic Gleason 8-10 disease. Adv Urol (2011) 0.75
Mechanism and Function of Angiogenin in Prostate Cancer. (2015) 0.75
Planning primary therapy. Cancer Imaging (2000) 0.75
Complications of radiotherapy: improving the therapeutic index. Cancer Imaging (2005) 0.75
Predictive preoperative factors for positive surgical margins in robotic radical prostatectomy in low-risk prostate cancer. Turk J Urol (2013) 0.75
The clinical impact of pathological review on selection the treatment modality for localized prostate cancer in candidates for brachytherapy monotherapy. World J Urol (2011) 0.75
Preoperative characteristics of the P.R.O.S.T.A.T.E. scores: a novel predictive tool for the risk of positive surgical margin after radical prostatectomy. J Cancer Res Clin Oncol (2016) 0.75
Stage T1c prostate cancer: defining the appropriate staging evaluation and the role for pelvic lymphadenectomy. World J Urol (1997) 0.75
Natural history of progression after PSA elevation following radical prostatectomy. JAMA (1999) 14.35
Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA (1994) 9.15
The development of human benign prostatic hyperplasia with age. J Urol (1984) 8.29
The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med (1992) 7.16
Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA (1992) 6.40
Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am (2001) 5.39
Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (1996) 5.06
Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol (1999) 4.85
Absence of p350 subunit of DNA-activated protein kinase from a radiosensitive human cell line. Science (1995) 4.19
Impotence following radical prostatectomy: insight into etiology and prevention. J Urol (1982) 4.08
Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology (2001) 3.99
Hereditary prostate cancer: epidemiologic and clinical features. J Urol (1993) 3.86
Cardiovascular purinoceptors. Physiol Rev (1990) 3.70
Neutrophils in development of multiple organ failure in sepsis. Lancet (2006) 3.64
The clinical usefulness of prostate specific antigen: update 1994. J Urol (1994) 3.64
A genetic linkage map for cattle. Genetics (1994) 3.64
Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate (1983) 3.53
Mandatory second opinion surgical pathology at a large referral hospital. Cancer (1999) 3.40
Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A (1992) 3.28
Family history and the risk of prostate cancer. Prostate (1990) 3.27
Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A (1994) 3.24
Sarcomas and related proliferative lesions of specialized prostatic stroma: a clinicopathologic study of 22 cases. Am J Surg Pathol (1998) 3.10
Telepathology diagnosis of prostrate needle biopsies. Hum Pathol (1997) 2.99
Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol (1996) 2.97
Using prostate-specific antigen to diagnose prostate cancer: sailing in uncharted waters. Ann Intern Med (1993) 2.77
Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. JAMA (1997) 2.73
Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. Hum Pathol (2001) 2.68
Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. N Engl J Med (1990) 2.67
Studies on the stereospecificity of closely related compounds which block postganglionic acetylcholine receptors in the guinea-pig ileum. J Med Chem (1973) 2.59
Localisation and stimulation of prostacyclin production in vascular cells. Nature (1978) 2.45
Utilization of oriented peptide libraries to identify substrate motifs selected by ATM. J Biol Chem (2000) 2.42
Vascular endothelial and smooth muscle cells in culture selectively release adenine nucleotides. Nature (1979) 2.42
Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer (1993) 2.40
Hepatitis B and hepatitis C in emergency department patients. N Engl J Med (1992) 2.39
Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology (2001) 2.38
Laboratory and bedside evaluation of portable glucose meters. Am J Clin Pathol (1995) 2.35
Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology (2000) 2.35
Uptake and metabolism of adenosine by pig aortic endothelial and smooth-muscle cells in culture. Biochem J (1978) 2.32
Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol (2001) 2.32
A comparison of the affinities of antagonists for acetylcholine receptors in the ileum, bronchial muscle and iris of the guinea-pig. Br J Pharmacol (1972) 2.31
Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol (2001) 2.31
Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med (1974) 2.27
Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci U S A (1990) 2.22
Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity toward cultured endothelial cells. Am J Pathol (1992) 2.19
Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: a diagnosis that should not be made. Am J Surg Pathol (2000) 2.19
Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am (1997) 2.07
Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol (2001) 2.07
Primary renal synovial sarcoma: molecular and morphologic delineation of an entity previously included among embryonal sarcomas of the kidney. Am J Surg Pathol (2000) 2.05
Stimulation of prostaglandin production through purinoceptors on cultured porcine endothelial cells. Biochem J (1983) 2.05
Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res (1996) 2.04
Werner syndrome protein is regulated and phosphorylated by DNA-dependent protein kinase. J Biol Chem (2001) 2.02
Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology (1995) 2.00
Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol (1996) 1.98
Exogenous ATP raises cytoplasmic free calcium in fura-2 loaded piglet aortic endothelial cells. FEBS Lett (1986) 1.98
Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab (2005) 1.98
DNA-dependent protein kinase catalytic subunit: a target for an ICE-like protease in apoptosis. EMBO J (1996) 1.97
Increasing incidence of minimal residual cancer in radical prostatectomy specimens. Am J Surg Pathol (1997) 1.97
Arrhythmia in heart and brain: KCNQ1 mutations link epilepsy and sudden unexplained death. Sci Transl Med (2009) 1.97
Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res (1993) 1.96
Metabolism of adenine nucleotides by ectoenzymes of vascular endothelial and smooth-muscle cells in culture. Biochem J (1980) 1.95
Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus. Arthritis Rheum (1998) 1.92
Stereoselectivity of ectonucleotidases on vascular endothelial cells. Biochem J (1983) 1.89
Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA (2000) 1.89
Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy. Am J Surg Pathol (2001) 1.87
Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol (1994) 1.87
Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol (1997) 1.86
Relationships between chemical structure and affinity for postganglionic acetylcholine receptors of the guinea-pig ileum. Br J Pharmacol (1974) 1.85
Leiomyosarcoma of the paratesticular region: a clinicopathologic study. Am J Surg Pathol (2001) 1.84
Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol (1988) 1.83
Fungal sinusitis: diagnosis with CT and MR imaging. Radiology (1988) 1.82
Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol (1988) 1.81
Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA (1997) 1.80
Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer. Urology (1997) 1.79
Age- and gender-specific reference ranges for hearing level and longitudinal changes in hearing level. J Acoust Soc Am (1996) 1.74